{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02844816\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["atezolizumab"]],"indication":"BCG-unresponsive high-risk non-muscle-invasive bladder cancer","name":"SWOG S1605","nct_id":"NCT02844816","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=swog-s1605-nct02844816. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity.","label":"Treatment (atezolizumab)","type":"EXPERIMENTAL"}],"collaborators":["Canadian Cancer Trials Group"],"completion_date":{"date":"2024-06-26","type":"ACTUAL"},"conditions":["Recurrent Bladder Urothelial Carcinoma","Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7","Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7","Stage I Bladder Urothelial Carcinoma AJCC v6 and v7"],"enrollment":{"count":172,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL 3280A","MPDL 328OA","MPDL-3280A","MPDL3280A","MPDL328OA","RG 7446","RG-7446","RG7446","RO 5541267","RO-5541267","RO5541267","Tecentriq"],"type":"DRUG"}],"last_update":"2025-05-22","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-06-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS)","timeFrame":"At 25 weeks"},{"measure":"Event-free Survival (EFS)","timeFrame":"18 months"}],"references":[{"citation":"Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM Jr, Lerner SP. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 Dec;84(6):536-544. doi: 10.1016/j.eururo.2023.08.004. Epub 2023 Aug 16.","pmid":"37596191","type":"DERIVED"}],"start_date":{"date":"2017-03-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT02844816"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/swog-s1605-nct02844816"}